research use only

Resmetirom (MGL-3196) THR-β agonist

Cat.No.S6663

Resmetirom (MGL-3196, VIA-3196) is a liver-directed, orally active, selective thyroid hormone receptor β(THR-β) agonist with an EC50 of 0.21 μM,shows 28-fold selective for THR-β over THR-α in a functional assay.
Resmetirom (MGL-3196) THR agonist Chemical Structure

Chemical Structure

Molecular Weight: 435.22

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 435.22 Formula

C17H12Cl2N6O4

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 920509-32-6 -- Storage of Stock Solutions

Synonyms VIA-3196 Smiles CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl

Solubility

In vitro
Batch:

DMSO : 87 mg/mL (199.89 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
THR-β [1]
(Cell-free assay)
0.21μM(EC50)
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04951219 Recruiting
Non-Alcoholic Fatty Liver Disease
Madrigal Pharmaceuticals Inc.
July 9 2021 Phase 3
NCT04197479 Completed
Non-Alcoholic Fatty Liver Disease
Madrigal Pharmaceuticals Inc.
December 16 2019 Phase 3
NCT04671069 Completed
Healthy
Madrigal Pharmaceuticals Inc.
July 26 2019 Phase 1
NCT03900429 Active not recruiting
NASH - Nonalcoholic Steatohepatitis
Madrigal Pharmaceuticals Inc.
March 28 2019 Phase 3
NCT04671056 Completed
Healthy
Madrigal Pharmaceuticals Inc.
November 9 2018 Phase 1
NCT03220165 Completed
Healthy
Madrigal Pharmaceuticals Inc.|Worldwide Clinical Trials
August 6 2017 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.